Project Grant R21CA297125
Award Date 9/5/25
Completion Date 8/31/27
Dollars Obligated $423K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21201, USA
Similar Awards
- This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $4,523,000.00 to the University of Maryland, Baltimore to conduct a first-in-human Phase 1 clinical trial using trispecific (CD19/CD20/CD22) CAR T cells for the treatment of relapsed/refractory B cell lymphoma. The 4-year project, running from September 2025 to September 2029, will evaluate the safety and feasibility of this novel cellular immunotherapy...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $604,627 to the Trustees of Dartmouth College to conduct research aimed at deconvoluting the heterogeneity of chimeric antigen receptor (CAR) T cells in order to engineer durable antitumor immunity. The research project, which runs from January 1, 2025 to December 31, 2029, will use dynamic lineage recording to understand how individual CAR T cell subsets behave in vivo and...
- The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $1,847,485 Project Grant to The University of Texas MD Anderson Cancer Center to advance next-generation CAR-NK (chimeric antigen receptor-modified natural killer) cell therapies targeting CD5-positive T-cell malignancies. The award, effective September 19, 2025 through August 31, 2029, will support the development and clinical testing of an engineered CAR-NK cell product expressing an anti-CD5 scFv, IL-15 for...
- The U.S. National Cancer Institute (NCI) has awarded a $398,997 Project Grant under the Cancer Treatment Research federal grant program (CFDA 93.395) to Immunogenik, Inc. to enhance cancer therapeutics with a novel 3-in-1 chimeric antigen receptor (CAR) T cell approach. The research aims to target tumor-associated myeloid cells, which can suppress anti-tumor immune responses, by inhibiting the immunosuppressive LAIR1 signaling pathway. Key deliverables include demonstrating the efficacy of LAIR1...
- This $195,766 federal Project Grant, awarded on December 19, 2024 by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research at Yale University to develop a mechano-transduction platform for enhancing chimeric antigen receptor (CAR) T-cell therapies for cancer immunotherapy. The key goals are to: 1) measure forces along immune receptors like the T-cell receptor and CAR using force sensors, and 2) engineer force transduction modules that can induce expression of...
- The National Cancer Institute (NCI) awarded a $1,477,396 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Beckman Research Institute of the City of Hope in Duarte, CA. The grant, awarded on December 1, 2024, supports a novel approach to enhance the efficacy and durability of CD19 chimeric antigen receptor (CAR) T-cell therapy for B-cell non-Hodgkin's lymphoma (B-NHL). The project involves selecting cytomegalovirus (CMV)-specific T cells, modifying them with a...
- The federal Project Grant award titled "HARNESSING B CELLS AFTER STEM CELL TRANSPLANT TO PRODUCE NOVEL CAR-TS" is funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) for a total of $415,257. The project period runs from July 3, 2025 to June 30, 2027. The award aims to leverage insights into B cell tolerance mechanisms after hematopoietic stem cell transplantation to engineer less toxic, more targeted immune cells that can eradicate hematological...
- The National Cancer Institute awarded a $176,040 Project Grant to The General Hospital Corporation (Massachusetts General Hospital) from July 1, 2025 to June 30, 2027 under the Cancer Research Manpower (CFDA 93.398) federal grant program. The goal of this project is to develop new strategies to engineer CAR-T cells that can overcome the cancer cell glycocalyx barrier in solid tumors. This will involve: (1) engineering CAR-T cells to strengthen the immune synapse by enhancing binding to the...
- This federal Project Grant award of $222,998.00 from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research at the University of California, San Diego (UCSD) to develop a novel virus-like particle (VLP) vector for engineering endogenous immune cells to express chimeric antigen receptors (CARs). The goal is to enable these engineered immune cells, including T cells, NK cells, and macrophages, to mediate potent killing of ovarian cancer cells. This...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $1,271,780.00 to the University of Pittsburgh to develop small molecule adaptors for precisely controlling universal chimeric antigen receptor (CAR) T cell therapies. The key objectives are to: 1) Develop small molecule adaptors for targeting universal CARs to multiple antigens, including tumor cells and immunosuppressive cells, 2) Enhance CAR targeting specificity using...